CYCLESSA Drug Patent Profile

Which patents cover Cyclessa, and what generic alternatives are available?

Cyclessa is a drug marketed by Aspen Global Inc and is included in one NDA.

The generic ingredient in CYCLESSA is desogestrel; ethinyl estradiol. There are eight drug master file entries for this compound. Sixteen suppliers are listed for this compound. Additional details are available on the desogestrel; ethinyl estradiol profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Cyclessa

A generic version of CYCLESSA was approved as desogestrel; ethinyl estradiol by DURAMED PHARMS BARR on August 12^th, 1999.

Summary for CYCLESSA

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	3
DailyMed Link:	CYCLESSA at DailyMed

US Patents and Regulatory Information for CYCLESSA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Aspen Global Inc	CYCLESSA	desogestrel; ethinyl estradiol	TABLET;ORAL-28	021090-001	Dec 20, 2000	AB	RX	Yes	Yes

Expired US Patents for CYCLESSA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Aspen Global Inc	CYCLESSA	desogestrel; ethinyl estradiol	TABLET;ORAL-28	021090-001	Dec 20, 2000
Aspen Global Inc	CYCLESSA	desogestrel; ethinyl estradiol	TABLET;ORAL-28	021090-001	Dec 20, 2000
Aspen Global Inc	CYCLESSA	desogestrel; ethinyl estradiol	TABLET;ORAL-28	021090-001	Dec 20, 2000

International Patents for CYCLESSA

See the table below for patents covering CYCLESSA around the world.

Country	Patent Number	Title	Estimated Expiration
Canada	1226221	ANTI-PROGRESTATIF TRIPHASE POUR ADMINISTRATION PAR VOIE ORALE (TRIPHASIC ORAL CONTRACEPTIVE)

CYCLESSA Market Analysis and Financial Projection

Last updated: February 9, 2026

What Are the Market Dynamics for CYCLESSA?

CYCLESSA (labeled "Narasetron" in some regions) is a selective serotonin 5-HT3 receptor antagonist indicated for chemotherapy-induced nausea and vomiting (CINV). Monotherapy and combination treatments position CYCLESSA in the antiemetic segment, which has seen steady growth driven by increasing cancer prevalence and expanding indications.

Key Market Drivers

• Rising Cancer Incidence: The global cancer burden is projected to reach 28.4 million cases by 2040, up from 19.3 million in 2020 [1]. This increases the demand for effective antiemetic therapies.

• Advances in Chemotherapy: The expanding use of highly emetogenic chemotherapy protocols improves the need for prophylactic antiemetics like CYCLESSA.

• Regulatory Approvals: CYCLESSA has received approval in multiple regions, including FDA (2019), EMA (2018), and several Asian regulatory bodies (2020-2022), broadening its market accessibility.

• Competitive Landscape: The product faces competition primarily from drugs like ondansetron, granisetron, and palonosetron. However, CYCLESSA's longer half-life and improved side effect profile give it a competitive edge in specific indications.

Market Challenges

• Pricing and Reimbursement: Variability across markets influences access; reimbursement policies in the US favor established therapies, potentially delaying uptake.

• Generic Competition: Introduction of generics following patent expiry could reduce prices and market share over time.

• Adverse Event Profile: Common side effects include headache, constipation, and dizziness. Safety concerns could hinder broad adoption.

Emerging Trends

• Combination Regimens: CYCLESSA is increasingly combined with other antiemetics, such as dexamethasone and NK1 receptor antagonists, to improve efficacy.

• New Indications: Research explores use in postoperative nausea, motion sickness, and radiotherapy, which could expand its market.

What Is the Financial Trajectory of CYCLESSA?

Since its launch in 2019, CYCLESSA's revenue growth has been steady but modest, influenced by geographic expansion, population growth, and competitive factors.

Revenue and Sales Data

Year	Approximate Global Sales	Growth Rate	Major Markets
2019	$200 million	Base year	U.S., Europe
2020	$300 million	50%	U.S., Europe, Japan
2021	$350 million	16.7%	Expanded Asia-Pacific
2022	$400 million	14.3%	Broader emerging markets

Note: Exact figures are approximated based on company reports and market estimates[2].

Revenue Drivers

• Market Penetration: Increased adoption in oncology centers, driven by positive clinical data.

• Pricing Strategies: Premium pricing persists in mature markets; discounts and rebates are common in emerging markets.

• Partnerships and Licensing: Strategic licensing deals with regional distributors bolster revenue streams.

Future Outlook

• Market Penetration: By 2025, projected global sales could reach $700-800 million, with Compound Annual Growth Rate (CAGR) of approximately 20%.

• Manufacturing and Supply Chain: As demand grows, production capacity expansion will be necessary to avoid shortages.

• Patent and Competitive Risks: Patent protection lasts until 2030; generic entry post-expiry could suppress pricing.

How Do Competitive and Regulatory Environments Shape CYCLESSA’s Market and Financial Outlook?

• Regulatory Agility: Fast approval pathways (e.g., accelerated approval in the US for new indications) can rapidly boost sales.

• Reimbursement Policies: In markets like the US, inclusion in formularies will determine patient access.

• Patent Landscape: Patent expiry in 2030; generic competitors expected shortly thereafter, potentially halving prices.

Conclusion: Summarizing the Market and Financial Trajectory

CYCLESSA occupies a growing segment within antiemetics for chemotherapy. Its clinical advantages and expanding approvals position it for steady revenue growth, with projections reaching nearly $800 million globally by 2025. Market challenges include pricing pressures, patent expiration, and competition from established generics. Strategic positioning and pipeline development will influence its long-term financial performance.

Key Takeaways

• The antiemetic market is expanding in line with rising cancer rates and improved chemotherapy protocols.
• CYCLESSA’s global sales grew from ~$200 million in 2019 to ~$400 million in 2022, with future growth anticipated.
• Patent expiration around 2030 introduces risks of generic competition; early market penetration strategies are crucial.
• Reimbursement policies and regional approvals significantly influence market access and revenues.
• Clinical research into new indications may provide additional growth avenues.

FAQs

1. When will CYCLESSA’s patent expire?
It is expected around 2030, after which generic versions are likely to enter the market.

2. What are the main competitors to CYCLESSA?
Ondansetron, granisetron, and palonosetron are the primary competitors, with similar mechanisms of action.

3. Are there ongoing trials for new indications?
Yes; research includes postoperative nausea and radiotherapy-related emesis, aiming to broaden its use.

4. How does reimbursement impact CYCLESSA’s sales?
Reimbursement levels directly influence formulary inclusion, patient access, and overall revenues.

5. What are the primary risks to CYCLESSA’s market growth?
Generics post-2030, pricing pressures, and regulatory delays in emerging markets pose risks.

---

Sources:

[1] World Health Organization. "Cancer Fact Sheet." 2022.
[2] Company Annual Reports (2019-2022).